CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical allogeneic hematopoietic stem cell transplantation: use of a low dose of post-allograft anti-lymphocytic serum.

Institut Paoli-Calmettes0 个研究点目标入组 27 人开始时间: 2024年4月5日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•adult with age = 60 or aged 50 to 59 with comorbidities (HCT-CI10 score = 3), haematological malignancies except for myeloproliferative syndrome and myelodysplastic syndrome, Patient having received an allograft within = 35 days, performed with the following modalities: o First allogeneic transplant, o Haploidentical donor, o Peripheral stem cell transplant, o Non-myeloablative Baltimore-type conditioning, delivered as standard in routine care, as reported in the literature (fludarabine, cyclophosphamide, total body irradiation), o Standard GVH prophylaxis in the context of haploidentical transplants (post-transplant cyclophosphamide, ciclosporin A and mycophenolate mofetil)., Patient discharged from aplasia within = 35 days, Signed informed Consent form, affiliation with a social security

•previous allogeneic transplant or organ transplant, presence of GVH, contraindication to treatment with thymoglobuline, Hypersensitivity to rabbit proteins or to any of the excipients listed in the Composition” section of the summary of product characteristics, pregnant women or may become pregnant (without effective contraception) or breast-feeding, Person in an emergency situation or unable to give informed consent form, Adult with a legal protection measure (adult under guardianship, curatorship or safeguard of justice), Unable to comply with medical follow-up for geographical, social or psychological reasons

发起方

Institut Paoli-Calmettes